Literature DB >> 15134674

Genetic testing for breast and ovarian cancer susceptibility: a family experience.

Marcia Van Riper1, Wendy C McKinnon.   

Abstract

The purpose of this article is to provide an overview of current knowledge concerning genetic testing for breast and ovarian cancer susceptibility. This overview includes 1) a brief history of genetic testing for breast and ovarian cancer susceptibility, 2) a review of factors that midwives and other health care providers need to consider before offering this type of testing to their clients, 3) management options for clients at high risk for hereditary breast and ovarian cancers, and 4) a discussion of preliminary findings from an ongoing study concerning the family experience of genetic testing, which illustrates some of the ethical issues that emerge for individuals and families during the family experience of genetic testing for breast and ovarian cancer susceptibility.

Entities:  

Mesh:

Year:  2004        PMID: 15134674     DOI: 10.1016/j.jmwh.2004.01.021

Source DB:  PubMed          Journal:  J Midwifery Womens Health        ISSN: 1526-9523            Impact factor:   2.388


  5 in total

1.  Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing.

Authors:  Wendy McKinnon; Shelly Naud; Taka Ashikaga; Rose Colletti; Marie Wood
Journal:  J Genet Couns       Date:  2007-06-27       Impact factor: 2.537

Review 2.  Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information.

Authors:  Gillian Nycum; Denise Avard; Bartha M Knoppers
Journal:  Eur J Hum Genet       Date:  2009-03-25       Impact factor: 4.246

Review 3.  Men's decision-making about predictive BRCA1/2 testing: the role of family.

Authors:  N Hallowell; A Ardern-Jones; R Eeles; C Foster; A Lucassen; C Moynihan; M Watson
Journal:  J Genet Couns       Date:  2005-06       Impact factor: 2.537

4.  Cancer genetic counselees' self-reported psychological distress, changes in life, and adherence to recommended surveillance programs 3-7 years post counseling.

Authors:  Afsaneh Hayat Roshanai; Richard Rosenquist; Claudia Lampic; Karin Nordin
Journal:  J Genet Couns       Date:  2009-02-11       Impact factor: 2.537

Review 5.  Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs.

Authors:  Yan Xu; Ana Johnson
Journal:  Pain Res Treat       Date:  2013-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.